A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
PK of FG-4592Hepatic InsufficiencyHealthy Subjects
Interventions
DRUG

FG-4592

Oral

Trial Locations (1)

Unknown

COMAC, Sofia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

FibroGen

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY